Quintiles announced a strategic alliance with Hospital Italiano of Buenos Aires as part of the company’s Prime Site program.
Quintiles announced a strategic alliance with Hospital Italiano of Buenos Aires as part of the company’s Prime Site program. Hospital Italiano is Quintiles’ first Prime Site in Latin America. A Prime Site is a large clinical institution selected by Quintiles to work together and enhance the institution’s infrastructure for conducting clinical trials. The new Prime Site at Hospital Italiano has dedicated research facilities, full-time study coordinators, a local College of American Pathologists (CAP)-accredited laboratory and full-service pharmacy. To date, Hospital Italiano has conducted more than 60 trials in 12 different therapy areas with Quintiles – comparable to other Quintiles Prime Sites, and delivered the required subjects for a variety of complex trials for the company.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.